<DOC>
	<DOCNO>NCT00098488</DOCNO>
	<brief_summary>This phase I trial study side effect best dose 17-N-allylamino-17-demethoxygeldanamycin give without rituximab treat patient relapse B-cell chronic lymphocytic leukemia prolymphocytic leukemia . Drugs use chemotherapy , 17-N-allylamino-17-demethoxygeldanamycin , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Monoclonal antibody may kill cancer cell leave chemotherapy . Giving 17-N-allylamino-17-demethoxygeldanamycin without rituximab may kill cancer cell .</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin With Without Rituximab Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia Prolymphocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) twice weekly 17-allylamino-17-demethoxygeldanamycin ( 17-AAG ) combination weekly rituximab patient relapse chronic lymphocytic leukemia ( CLL ) . II . To examine pharmacology twice weekly 17-AAG combination weekly rituximab patient relapse CLL . SECONDARY OBJECTIVES : I . To evaluate toxicity ( use NCI CTCAE v3.0 criterion ) preliminary efficacy twice weekly 17-AAG use combination weekly rituximab patient population . II . To examine kinetics depletion PDK1/AKT-related protein , mutant p53 up-regulation alternative target mediate resistance therapy follow treatment twice weekly 17-AAG ; relationship spontaneous drug-induced apoptosis patient relapse CLL . III . To examine immunologic effect twice weekly 17-AAG , conjunction weekly rituximab , patient relapse CLL . IV . To evaluate toxicity preliminary efficacy twice weekly 17-AAG single agent patient population . OUTLINE : This multicenter , dose-escalation study 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) . Patients receive 17-AAG intravenously ( IV ) 2 hour day 1 , 4 , 8 , 11 , 15 18 ( course 1 ) . Patients achieve ≥ 25 % reduction measurable disease course 1 receive additional course single-agent 17-AAG approximately 10 day later absence disease progression unacceptable toxicity provide absolute lymphocyte count continue decrease . Patients fail achieve 25 % reduction measurable disease course 1 OR disease progression course 1 2 single-agent 17-AAG proceed combination therapy comprise 17-AAG IV 2 hour day 1 , 4 , 8 , 11 , 15 , 18 , 22 ; rituximab IV 4 hour day 1 2 1 hour day 4 , 8 , 15 , 22 absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos 17-AAG single agent combination rituximab maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 2 month every 3 month 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm Bcell chronic lymphocytic leukemia prolymphocytic leukemia require treatment , define 1 follow criterion : Massive progressive splenomegaly and/or lymphadenopathy Anemia ( hemoglobin &lt; 11 g/dL ) OR thrombocytopenia ( platelet count &lt; 100,000/mm^3 ) Weight loss &gt; 10 % within past 6 month Grade 2 3 fatigue Fevers &gt; 100.5°F night sweat &gt; 2 week evidence infection Progressive lymphocytosis increase &gt; 50 % 2 month period OR anticipate double time &lt; 6 month Relapsed disease Failed prior fludarabine pentostatin therapy OR receive fludarabine Lymphocyte count ≥ 5,000/mm^3 Performance status ECOG 02 Performance status Karnofsky 60100 % More 12 week Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 2.0 mg/dL LVEF &gt; 40 % MUGA QTc &lt; 450 msec male patient &lt; 470 msec female patient Resting ejection fraction ≥ 50 % MUGA echocardiogram No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No significant cardiac disease include follow : New York Heart Association class III IV heart failure History myocardial infarction within past year History uncontrolled dysrhythmias Active ischemic heart disease within past year Poorly control angina No history serious ventricular arrhythmia ( e.g. , ventricular fibrillation , history symptomatic sustain ventricular tachycardia , nonsustained ventricular tachycardia &gt; 3 beat within past 6 month ) No history cardiac toxicity due anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride ) No cardiac symptom ≥ grade 2 DLCO ( i.e. , oxygen diffusion capacity ) ≥ 80 % pulmonary function test Resting exercise oxygen saturation ≥ 90 % pulse oximetry No pulmonary symptom ≥ grade 2 No history pulmonary toxicity due bleomycin carmustine No significant , symptomatic pulmonary disease require oxygen medication No ongoing pulmonary symptom ≥ grade 2 include follow : Dyspnea exertion Paroxysmal nocturnal dyspnea Significant pulmonary disease ( e.g. , chronic obstructive restrictive pulmonary disease ) No Medicare requirement home oxygen ( e.g. , rest O_2 saturation ≥ 90 % desaturation ≥ 90 % exertion ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No history allergic reaction attribute compound similar chemical biologic composition 17Nallylamino17demethoxygeldanamycin No history serious allergic reaction egg No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness would preclude study participation More 3 month since prior rituximab recover More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover More 4 week since prior radiotherapy recover No prior radiotherapy potentially include heart field ( e.g. , mantle ) No history chest radiation No concurrent medication prolong may prolong QTc No concurrent antiarrhythmic drug No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>